Overall rank by patents
#6,135
Across all tracked assignees
USPTO PatentsView assignee record - 55 granted patents across 12 technology areas, active 2015–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
The verdict
Dyax holds 55 US patents across 12 technology areas, rank #6,135 of 50,000 tracked assignees.
Dyax Corp. has been granted 55 US utility patents between 2015 and 2021, placing Dyax Corp. at rank #6,135 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.6 claims per patent with primary concentration in C07K (PEPTIDES). As a US Corporation, Dyax Corp. is one of the more focused assignees in the PatentsView dataset. By volume, Dyax sits between Curevac SE (55 patents, rank #6,131) and East Carolina University (55 patents, rank #6,139) - the closest US assignees by grant volume. The composite Innovation Score of 36.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 12 grants, compared with 43 in the 2015–2019 window, a -72% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Dyax Corp.'s 16.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 12 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Dyax Corp. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
CureVac SE
55 patents
Custom Molded Products, LLC
55 patents
DENTAL IMAGING TECHNOLOGIES CORPORATION
55 patents
DT SWISS INC.
55 patents
ELKAY MANUFACTURING COMPANY
55 patents
ENZO LIFE SCIENCES, INC.
55 patents
EUGENE TECHNOLOGY CO., LTD.
55 patents
East Carolina University
55 patents
Dyax Corp.
55 patents
What this shows Dyax holds 55 patents at rank #6,135, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #6,135 in granted patent volume.
Other assignees with the most granted patents in Dyax's primary technology class.
Dyax's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
36 Top 47% higher than 53% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 12 | 21.8% |
| 2016 | 8 | 14.5% |
| 2017 | 13 | 23.6% |
| 2018 | 4 | 7.3% |
| 2019 | 6 | 10.9% |
| 2020 | 9 | 16.4% |
| 2021 | 3 | 5.5% |
Top 12 of 12 technology areas
Overall rank by patents
#6,135
Across all tracked assignees
36.1 out of 100
How to use this portfolio
Dyax's 55 grants land it in the top 47% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.